New Alzheimer's Drug Approval Expands Treatment Options — and Creates Coverage Questions

Health Affairs This Week

Content provided by Health Affairs. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Health Affairs or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

1M ago 15:38

MP3•Episode home

Learn more about the Robert Wood Johnson Health Policy Fellows Program.

Health Affairs' Jeff Byers welcomes Senior Editor Leslie Erdelack to the program to discuss FDA's recent approval of an Alzheimer's treatment drug, Lilly’s Kisunla, how private insurers and Medicare may cover the drug, and the emerging new class of drugs surrounding Alzheimer's treatment.

We announced the winner for our You're A Health Policy Wonk If... contest this week!

Until July 20, we are having a flash sale on Health Affairs Insider membership. Use the code HealthWonkLife for $30 off the normal Insider price.

Check out our Request For Abstracts page for the April 2025 theme issue focusing on Food, Nutrition, and Health.

Related Articles:

Approval of Newest Alzheimer’s Drug Will Accelerate New Era of Treatment by Peter Loftus and Joseph Walker (Wall Street Journal)
Press Release: Lilly's Kisunla Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease

The Robert Wood Johnson Health Policy Fellows Program application is now open.

176 episodes

#News #Government #Health Affairs #Health Policy #Affordable Care Act #Individual Mandate #Medicare #Medicaid #Health Inequalities #ACA #CMS #HHS